Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses
Brief Summary: The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.


Options:
A: Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPPesc | Arm Label: Experimental arm; Type: EXPERIMENTAL; Interventions: Drug: BEACOPPesc - ABVD - PET2 | Intervention Type: DRUG; Name: BEACOPPesc; Assigned to Arm(s): Standard arm | Intervention Type: DRUG; Name: BEACOPPesc - ABVD - PET2; Assigned to Arm(s): Experimental arm
B: Arm Label: Treatment (chemotherapy and F-18 PET/CT); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Doxorubicin Hydrochloride, Drug: Procarbazine Hydrochloride, Drug: Vinblastine Sulfate, Drug: Dacarbazine, Drug: Cyclophosphamide, Drug: Etoposide phosphate, Drug: prednisone, Drug: Radiation Therapy, Radiation: Fludeoxyglucose F-18, Procedure: computed tomography, Procedure: Positron Emission Tomography | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Procarbazine Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Vinblastine Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Etoposide phosphate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Radiation Therapy; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: RADIATION; Name: Fludeoxyglucose F-18; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: computed tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: Positron Emission Tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT)
C: Arm Label: PET pos; Type: EXPERIMENTAL; Interventions: Drug: ESCALATED BEACOPP | Arm Label: PET negative; Type: OTHER; Interventions: Drug: CONVENTIONAL ABVD | Intervention Type: DRUG; Name: ESCALATED BEACOPP; Assigned to Arm(s): PET pos | Intervention Type: DRUG; Name: CONVENTIONAL ABVD; Assigned to Arm(s): PET negative
D: Arm Label: Arm A; Type: OTHER; Interventions: Drug: ABVD | Arm Label: Arm B; Type: OTHER; Interventions: Drug: ABVD and Radiotherapy | Intervention Type: DRUG; Name: ABVD; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: ABVD and Radiotherapy; Assigned to Arm(s): Arm B

Answer: C